Cytonics

We’re not just aligned with biotech’s biggest trends — we’re built for them. Here’s why Cytonics is uniquely positioned to succeed in today’s capital markets.

1️⃣ Solving a $393B Problem

Osteoarthritis affects over 500 million people globally, yet there’s no disease-modifying treatment. CYT-108 is designed to change that (1) — and our success with APIC™, NIH grants, and clinical trials demonstrate that the science is already being validated.

2️⃣ We’re Exactly Where Investors Are Looking

Biotech investors are prioritizing Phase 2-ready companies, with late-stage assets attracting 38% more funding than early-stage bets (2). Our $20M raise is laser-focused on CYT-108’s Phase 2 program — not speculative pipelines or bloated burn rates.

3️⃣ M&A-Ready Assets Win

Big Pharma is sitting on $1.5 trillion in firepower and is hungry for Phase 2 assets to replenish pipelines (3). With 25 issued patents and a clinical-stage OA platform, Cytonics checks the boxes for near-term strategic interest.

4️⃣ First-in-Class & Precision-Ready

The FDA is favoring first-in-class therapies (48% of 2025 approvals) (1,4). CYT-108’s novel mechanism — inhibiting cartilage-degrading enzymes and inducing cartilage synthesis — is built to lead, not follow. Paired with our FACT™ diagnostic, we’re aligning with the precision medicine boom driving biotech IPOs (2,4).

5️⃣ We’ve De-Risked the Model

While most early-stage biotechs are scrambling for Series B funding, Cytonics is ahead of the curve. Our model combines crowdfunding, NIH grants, and industry partnerships to fuel progress — and avoid dilution. In today’s volatile capital markets, that’s a serious edge.

💡 What It All Means

We believe that the investment thesis of clinical-stage biotech companies (like Cytonics) is strengthened by current sector dynamics, including

  • M&A resurgence: Notable deals in 2025 indicate a revitalized interest in biotech acquisitions. 120% average acquisition premium in biotech M&A (5)
  • Phase 2 focus: Increased follow-on financing for clinical-stage assets. 64% jump in Phase 2 financing (2)

Cytonics combines validated clinical science, robust IP, and a capital-efficient development strategy. In a market where biotech is regaining its momentum, we’re not just riding the wave—we’re building it.

👉 Become a shareholder

References

  1. https://www.ppd.com/blog/2025-biopharma-biotech-trends/     
  2. https://www.mercalis.com/resources/biotech-funding-in-2025/      
  3. https://www.alpha-sense.com/blog/trends/biotech-pharma-m-and-a-2025-outlook/  
  4. https://www.labiotech.eu/in-depth/biotech-trends-2025/     
  5. https://www.rbccm.com/en/story/story.page?dcr=templatedata%2Farticle%2Fstory%2Fdata%2F2025%2F02%2Funcertainty-reigns-but-opportunity-persists-for-biotechs-2025       

Reg A Disclaimer

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. You may obtain a copy of the offering circular here: https://www.sec.gov/Archives/edgar/data/1421744/000110465925024346/tm2427963d11_253g2.htm

Leave a Reply

I’m Joey Bose, CEO of Cytonics

I started this blog to track our drug development journey as we take on the Boogeyman of regenerative medicine – osteoarthritis (OA). If successful, we will have developed the first and only “true” disease-modifying treatment for OA, succeeding where Big Pharma has repeatedly failed, and forever changing the lives of 600M suffering people worldwide. And if that wasn’t enough, we will have done so without a dime of Venture Capital or institutional support. Cytonics is a company For the People, By the People, and we are extremely proud of our grassroots approach to biopharmceutical development! Want to get involved? invest.cytonics.com